clinical trial · NCT02504372
Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)
Merck Sharp & Dohme LLC·phase3·completed·n = 1,177
Non-small Cell Lung CancerPembrolizumabPlacebo
brief summary
In this study, participants with Stage IB/II-IIIA non-small cell lung cancer (NSCLC) who have undergone surgical resection (lobectomy or pneumonectomy) with or without adjuvant chemotherapy will be treated with pembrolizumab or placebo. The primary study hypothesis is that pembrolizumab will provide improved disease-free survival (DFS) versus placebo.
started
Nov 6, 2015
primary completion
Jan 24, 2023
completion
Jan 21, 2026
last updated
Nov 17, 2026
official title
A Randomized, Phase 3 Trial With Anti-PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) Versus Placebo for Patients With Early Stage NSCLC After Resection and Completion of Standard Adjuvant Therapy (PEARLS)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol